Across the recent three months, 18 analysts have shared their insights on Biogen (NASDAQ:BIIB), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 4 | 3 | 11 | 0 | 0 |
Last 30D | 0 | 0 | 1 | 0 | 0 |
1M Ago | 1 | 0 | 2 | 0 | 0 |
2M Ago | 0 | 0 | 3 | 0 | 0 |
3M Ago | 3 | 3 | 5 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of $300.00, and a low estimate of $138.00. A 16.73% drop is evident in the current average compared to the previous average price target of $257.94.
Interpreting Analyst Ratings: A Closer Look
The standing of Biogen among financial...
Login or create a forever free account to read this news
Sign up/Log in
Comment(0)
Reason For Report